Announcing a new article publication for BIO Integration journal. Neurologic disorders currently affect approximately 100 million people worldwide.

The FDA approved betibeglogene autotemcel (beti-cel; Zynteglo) for adult and pediatric patients with transfusion-dependent ...

The Google cofounder has donated more than $1.5 billion to Parkinson’s research. Now, as he takes on autism, he’s also ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the ...

Gain's lead program in Parkinson's disease has been awarded funding support from The Michael J. Fox Foundation for ...

We spend billions searching for the cures to chronic illnesses while neglecting research that could make the daily lives of ...

For the last 10 years, the only effective treatment for hypophosphatasia (HPP) has been an enzyme replacement therapy that ...

FDA aligned on single-arm Phase 3 study to support potential accelerated and full approvalOn track to dose first patient in Phase 3 trial in ...

Researchers are enhancing the best features of AAV capsids and overcoming their limitations to accelerate gene-based therapies.

Amanda Ibe-Enwo is a distinguished researcher at Voyager Therapeutics, a biotechnology company based in Massachusetts, USA.

South San Francisco, CA, January 30, 2025 – The California Institute for Regenerative Medicine (CIRM), one of the world’s largest institutions dedicated to regenerative medicine, has awarded nearly ...